eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 69
Short communication

ER–/PR+ subset of invasive breast carcinoma (IBC): a distinct phenotype with good prognosis

Simona Stolnicu, Orsolya Bauer, Adrian Naznean, Cristian Podoleanu, Rareş Georgescu

Pol J Pathol 2018; 69 (3): 311-313
Online publish date: 2018/11/20
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
The expression of the estrogen (ER) and progesterone (PR) receptors in IBC patients represents a well-know prognostic and predictive factor. The existence of ER–/PR+ as a distinct phenotype, however, is controversial as well as is its prognostic significance. The aim of the study was to assess the incidence and prognosis in patients with ER–/PR+ IBC.

One hundred and twelve patients with IBC were analyzed regarding ER/PR profile and survival. GraphPad prism 6 for Windows and Kaplan Mayer curve were used to determine overall survival (OS) and disease-free survival (DFS), with p < 0.05 as statistically significant.

Of the 112 IBC patients, 75% were ER+/PR–, 16.07% were ER–/PR–, 7.14% were ER+/PR– and only 1.78% were ER–/PR+. OS was 100% in the ER–/PR+ group and 91.6% in the ER+/PR+ group. The lowest OS was found in the ER-/PR- group (72.2%), while OS was 100% in ER–/PR+ group. Regarding DFS, there were no statistically significant differences in the four groups (p = 0.11), although the highest DFS was found in the ER–/PR+ group (100%). ER–/PR+ tumors were associated with younger age (p = 0.72), smaller tumor diameter (p = 0.27), absence of lymph node metastases, and HER2 overexpression.

Our results suggest that ER–/PR+ cases represent the rarest phenotype in IBC cases but its association with the best OS and DFS in other ER/PR phenotypes indicates an independent predictive value of PR for treatment considerations.

breast pathology, breast cancer, immunohistochemistry, hormone receptors, management

Cserni G, Francz M, Kalman E, et al. Estrogen receptor negative and progesterone receptor positive breast carcinomas- how frequent are they? Pathol Oncol Res 2011; 17: 663-668.
Hefti MM, Hu R, Knoblauch NW, et al. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res 2013; 15: R68.
Schrott W, Winter S, Buttner F, et al. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype. Breast Cancer Res Treat 2016; 155: 85-97.
Chan M, Chang MC, Gonzales R, et al. Outcomes of estrogen receptor negative and progesterone receptor positive breast cancer. PlosOne 2015; 10: e0132449.
Itoh M, Iwamoto T, Matsuoka J, et al. Estrogeb receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancer. Breast Cancer Res Treat 2014; 143: 403-409.
Shen T, Brandwein-Gensler M, Hameed O, et al. Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer. Hum Pathol 2015; 46: 1776-784.
Ahmed SS, Thike AA, Zhang K, et al. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group. J Clin Pathol 2017; 70: 320-326.
NCCN Clinical practice guidelines in oncology. Breast Cancer, NCCN.org 2017.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe